Menu

FDA Rejects China's Pioneering Lung Cancer Drug
📰

FDA Rejects China's Pioneering Lung Cancer Drug

Business - Latest - Google News·about 19 hours ago
#87ZdVkcH
#world#news#newser#trial#ivonescimab
Reading 0:00
15s threshold

Agency cites lack of survival benefit in Western trial of ivonescimab

Posted Nov 16, 2026 9:29 AM CST

A closely watched cancer drug out of China just hit a major roadblock in the US. Florida-based Summit Therapeutics, which holds US rights to ivonescimab, said Sunday the FDA has declined to approve the infusion treatment for certain patients with advanced lung cancer after a key global trial failed to show it helped people live longer compared with chemotherapy alone, per the New York Times . The drug did slow disease progression, and Summit argued that slow trial enrollment masked a survival benefit, but regulators were not convinced by the company's additional, after-trial analyses.

Ivonescimab is designed to hinder two proteins, one that helps cancer avoid immune responses and another that supplies blood to tumors, per Reuters .…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.